Payment overview · 2025
General Payments
$1,037.10
49 reported records · 17 companies
Healthcare provider profile · identity verified
Marshall J Keilson, MD
Allopathic & Osteopathic Physicians|Neuromusculoskeletal Medicine, Sports Medicine · BROOKLYN, NY · NPI 1528068954
Verified facts
What the public records show
CMS Open Payments records show Marshall J Keilson, MD received $1,037.10 in general payments during 2025 across 49 reported records.
PFIZER INC. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nuplazid by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tecfidera by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $172.50 | 16.6% | 10 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $146.65 | 14.1% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $116.65 | 11.2% | 6 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $94.06 | 9.1% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $80.96 | 7.8% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$67.37 | 6.5% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.92 | 5.5% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $50.91 | 4.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.89 | 4.8% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.02 | 4.5% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $38.41 | 3.7% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $26.63 | 2.6% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$23.76 | 2.3% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.75 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.19 | 1.7% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $14.76 | 1.4% | 1 | 2025 |
| Validus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.67 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,037.10 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $146.65 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $120.57 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $120.57 | 7 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $116.65 | 6 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $80.96 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $70.05 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $67.37 | 3 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $62.42 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $56.92 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $51.93 | 3 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $51.93 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $50.91 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $49.89 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $47.02 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| EQUETRO Normalized: equetro |
Drug | Validus Pharmaceuticals LLC | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 438 | 56 |
| Memantine Hcl | Memantine Hcl | 405 | 74 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 250 | 47 |
| Divalproex Sodium | Divalproex Sodium | 232 | 34 |
| Donepezil Hcl | Donepezil Hcl | 227 | 45 |
| Gabapentin | Gabapentin | 181 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 30 |
| Divalproex Sodium Er | Divalproex Sodium | 140 | 18 |
| Lacosamide | Lacosamide | 118 | 12 |
| Lamotrigine | Lamotrigine | 108 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 106 | 19 |
| Phenobarbital | Phenobarbital | 86 | suppressed |
| Topiramate | Topiramate | 82 | 12 |
| Baclofen | Baclofen | 77 | 12 |
| Carbamazepine Er | Carbamazepine | 76 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 72 | suppressed |
| Primidone | Primidone | 70 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 12 |
| Clobazam | Clobazam | 51 | suppressed |
| Lamotrigine Er | Lamotrigine | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Carbamazepine | Carbamazepine | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 40 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 29 | suppressed |
| Rytary | Carbidopa/Levodopa | 26 | suppressed |
| Zonisamide | Zonisamide | 26 | suppressed |
| Modafinil | Modafinil | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Fingolimod | Fingolimod Hcl | 21 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 17 | suppressed |
| Aubagio | Teriflunomide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Lamictal | Lamotrigine | 15 | suppressed |
| Copaxone | Glatiramer Acetate | 14 | suppressed |
| Dalfampridine Er | Dalfampridine | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Tegretol Xr | Carbamazepine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Rufinamide | Rufinamide | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,037.10 · 49 records | PFIZER INC. | BRIUMVI, DAYBUE, EQUETRO, KESIMPTA, LEQEMBI, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, QULIPTA, Symbravo, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error